Cost-Effectiveness of Once-Daily Single-Inhaler COPD Triple Therapy in Spain: IMPACT Trial

References

• GOLD. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease; 2020. Available from: www.goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf. Accessed March 13, 2020.
   Google Scholar
• Soriano JB, Rojas-Rueda D, Alonso J, et al. The burden of disease in Spain: results from the global burden of disease 2016. Med Clin. 2018;151(5):171–190. doi:10.1016/j.medcli.2018.05.011
   PubMed Web of Science ®Google Scholar
• Lopez-Campos JL, Tan W, Soriano JB. Global burden of COPD. Respirology. 2016;21(1):14–23. doi:10.1111/resp.12660
   PubMed Web of Science ®Google Scholar
• Iheanacho I, Zhang S, King D, Rizzo M, Ismaila AS. Economic burden of Chronic Obstructive Pulmonary Disease (COPD): a systematic literature review. Int J Chron Obstruct Pulmon Dis. 2020;15:439–460. doi:10.2147/copd.s234942
   PubMed Web of Science ®Google Scholar
• Izquierdo Alonso J. The burden of COPD in Spain: results from the Confronting COPD survey. Respir Med. 2003;97(Suppl C):S61–69. doi:10.1016/S0954-6111(03)80026-4
   PubMed Web of Science ®Google Scholar
• Ministerio de Sanidad y Politica Social. Estrategia en EPOC del Sistema Nacional de Salud; 2019. Available from: www.mscbs.gob.es/organizacion/sns/planCalidadSNS/docs/EstrategiaEPOCSNS.pdf. Accessed May 1, 2020.
   Google Scholar
• Miravitlles M, Soler-Cataluña JJ, Calle M, et al. Spanish Guidelines for Management of Chronic Obstructive Pulmonary Disease (GesEPOC) 2017. Pharmacological treatment of stable phase. Arch Bronconeumol. 2017;53(6):324–335. doi:10.1016/j.arbres.2017.03.018
   PubMed Web of Science ®Google Scholar
• Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–1680. doi:10.1056/NEJMoa1713901
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Galdiz JB, Huerta A, Villacampa A, Carcedo D, Garcia-Rio F. Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patients. Int J Chron Obstruct Pulmon Dis. 2016;11:123–132. doi:10.2147/copd.s94006
   PubMed Web of Science ®Google Scholar
• Driessen MT, Whalen J, Seewoodharry Buguth B, et al. Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective. Respir Res. 2018;19(1):224. doi:10.1186/s12931-018-0916-7
   PubMed Web of Science ®Google Scholar
• Capel M, Mareque M, Alvarez CJ, Lindner L, Oyaguez I. Cost-effectiveness of fixed-dose combinations therapies for chronic obstructive pulmonary disease treatment. Clin Drug Investig. 2018;38(7):611–620. doi:10.1007/s40261-018-0646-0
   PubMed Web of Science ®Google Scholar
• Atienza L, Benjamin N, Schroeder M, et al. Impact of once-daily single inhaler triple therapy on healthcare resource utilization and associated costs in COPD patients in Spain. Eur Respir J. 2018;52:PA3155.
   Web of Science ®Google Scholar
• Benjamin N, Huerta A, Biswas C, et al. Cost-effectiveness of a new single inhaler triple therapy versus a dual inhaled corticosteroid plus long-acting beta agonist in patients with COPD in Spain. Value Health. 2018;21(Suppl 3):CE2. doi:10.1016/j.jval.2018.09.014
   Web of Science ®Google Scholar
• Schroeder M, Benjamin N, Atienza L, et al. Cost-effectiveness analysis of a once-daily single-inhaler triple therapy for patients with Chronic Obstructive Pulmonary Disease (COPD) Using the FULFIL trial: a Spanish perspective. Int J Chron Obstruct Pulmon Dis. 2020;15:1621–1632. doi:10.2147/COPD.S240556
   PubMed Web of Science ®Google Scholar
• Exuzides A, Colby C, Briggs AH, et al. Statistical modeling of disease progression for chronic obstructive pulmonary disease using data from the ECLIPSE study. Med Decis Making. 2017;37(4):453–468. doi:10.1177/0272989x15610781
   PubMed Web of Science ®Google Scholar
• Risebrough NA, Briggs A, Baker TM, et al. Validating a model to predict disease progression outcomes in patients with COPD. Value Health. 2014;17(7):A560–561. doi:10.1016/j.jval.2014.08.1852
   PubMed Web of Science ®Google Scholar
• Tabberer M, Gonzalez-McQuire S, Muellerova H, et al. Development of a conceptual model of disease progression for use in economic modeling of chronic obstructive pulmonary disease. Med Decis Making. 2017;37(4):440–452. doi:10.1177/0272989X16662009
   PubMed Web of Science ®Google Scholar
• Briggs AH, Baker T, Risebrough NA, et al. Development of the Galaxy chronic obstructive pulmonary disease (COPD) model using data from ECLIPSE: internal validation of a linked-equations cohort model. Med Decis Making. 2017;37(4):469–480. doi:10.1177/0272989X16653118
   PubMed Web of Science ®Google Scholar
• Big-Pac RLD. Pacientes en tratamiento farmacológico para la EPOC. Movimiento Total Anual a Q2. Real Life Data SLU; 2018. Available from: www.rlifedata.com. Accessed March 16, 2020.
   Google Scholar
• Instituto Nacional de Estadistica (National Institute of Statistics). INEbase- Standard of living and living conditions (CPI)- Consumer price and housing indices; 2019. Available from: www.ine.es/dyngs/INEbase/en/categoria.htm?c=Estadistica_P&cid=1254735976604. Accessed March 16, 2020.
   Google Scholar
• Lopez-Bastida J, Oliva J, Antonanzas F, et al. Spanish recommendations on economic evaluation of health technologies. Eur J Health Econ. 2010;11(5):513–520. doi:10.1007/s10198-010-0244-4
   PubMed Web of Science ®Google Scholar
• Sacristan JA, Oliva J, Del Llano J, Prieto L, Pinto JL. ¿Qué es una tecnología sanitaria eficiente en España? [What is an efficient health technology in Spain?]. Gac Sanit. 2002;16(4):334–343. Spanish. doi:10.1016/s0213-9111(02)71933-x
   PubMedGoogle Scholar
• De Cock E, Miravitlles M, Gonzalez-Juanatey JR, Azanza-Perea JR. Valor umbral del coste por año de vida ganado para recomendar la adopción de tecnologías sanitarias en España: evidencias procedentes de una revisión de la literatura. Pharmacoecon Span Res Artic. 2007;4:97–107. doi:10.1007/BF03320930
   Google Scholar
• Sacristan JA, Oliva J, Campillo-Artero C, et al. ¿Qué es una intervención sanitaria eficiente en España en 2020? [What is an efficient health intervention in Spain in 2020?]. Gac Sanit. 2020;34(2):189–193. Spanish. doi:10.1016/j.gaceta.2019.06.007
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543–1554. doi:10.1056/NEJMoa0805800
   PubMed Web of Science ®Google Scholar
• Ismaila AS, Risebrough N, Schroeder M, et al. Cost-effectiveness of once-daily single-inhaler triple therapy in COPD: the IMPACT trial. Int J Chron Obstruct Pulmon Dis. 2019;14:2681–2695. doi:10.2147/copd.s216072
   PubMed Web of Science ®Google Scholar
• Hoogendoorn M, Feenstra TL, Asukai Y, et al. Cost-effectiveness models for chronic obstructive pulmonary disease: cross-model comparison of hypothetical treatment scenarios. Value Health. 2014;17(5):525–536. doi:10.1016/j.jval.2014.03.1721
   PubMed Web of Science ®Google Scholar
• Starkie HJ, Briggs AH, Chambers MG. Pharmacoeconomics in COPD: lessons for the future. Int J Chron Obstruct Pulmon Dis. 2008;3(1):71–88.
   PubMedGoogle Scholar
• Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(10):1005–1012. doi:10.1056/NEJMoa021322
   PubMed Web of Science ®Google Scholar
• Hoogendoorn M, Feenstra TL, Asukai Y, et al. External validation of health economic decision models for Chronic Obstructive Pulmonary Disease (COPD): report of the third COPD modeling meeting. Value Health. 2017;20(3):397–403. doi:10.1016/j.jval.2016.10.016
   PubMed Web of Science ®Google Scholar
• Lewis HB, Schroeder M, Gunsoy NB, et al. Evaluating patient preferences of maintenance therapy for the treatment of chronic obstructive pulmonary disease: a discrete choice experiment in the UK, USA and Germany. Int J Chron Obstruct Pulmon Dis. 2020;15:595–604. doi:10.2147/COPD.S221980
   PubMed Web of Science ®Google Scholar
• Lipson DA, Barnhart F, Boucot I, et al. Exacerbation outcomes with LAMA/LABA and ICS/LABA in high risk COPD patients in the IMPACT trial. Eur Respir J. 2018;52(Suppl 62):PA4384.
   Google Scholar
• Jones PW. The COPD Assessment Test: what have we learned over its first 5 years? Eur Respir J. 2014;44(4):833–834. doi:10.1183/09031936.00125214
   PubMed Web of Science ®Google Scholar